Cargando…
Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines
Sulfonylureas (SUs) are one of the commonly prescribed oral anti-hyperglycemic agents (AHA) in low- and middle-income countries (LMICs), either in combination with metformin therapy or alone. However, concern about cardiovascular safety has limited the use of SUs in the management of type 2 diabetes...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854230/ https://www.ncbi.nlm.nih.gov/pubmed/35185350 http://dx.doi.org/10.1177/11795514221074663 |
_version_ | 1784653402567868416 |
---|---|
author | Mohan, Viswanathan Saboo, Banshi Khader, Jabbar Modi, Kirtikumar D Jindal, Sushil Wangnoo, Subhash Kumar Amarnath, Sugumaran |
author_facet | Mohan, Viswanathan Saboo, Banshi Khader, Jabbar Modi, Kirtikumar D Jindal, Sushil Wangnoo, Subhash Kumar Amarnath, Sugumaran |
author_sort | Mohan, Viswanathan |
collection | PubMed |
description | Sulfonylureas (SUs) are one of the commonly prescribed oral anti-hyperglycemic agents (AHA) in low- and middle-income countries (LMICs), either in combination with metformin therapy or alone. However, concern about cardiovascular safety has limited the use of SUs in the management of type 2 diabetes mellitus (T2DM). Additionally, lack of uniformity in the national and international guidelines regarding the positioning of SUs in the management of diabetes has also been reported. The objective of this review was to assess the various national and international guidelines on diabetes management and understand the recommendations specific to SUs in various scenarios. A total of 33 national and international guidelines on the management of T2DM published in English were evaluated. These guidelines have considered the latest evidence and suggest the use of certain second-generation SUs as second-line therapy or in combination with other AHAs in select population and specific scenarios. Identification of the appropriate population, classification based on underlying risk, thorough assessment of the comorbid conditions, and a step-wise approach for the selection of appropriate SUs is essential for the effective management of T2DM. Additionally, cost-to–benefit ratio should be considered, particularly in LMICs, and SUs could continue to play an important role in such settings. |
format | Online Article Text |
id | pubmed-8854230 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-88542302022-02-19 Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines Mohan, Viswanathan Saboo, Banshi Khader, Jabbar Modi, Kirtikumar D Jindal, Sushil Wangnoo, Subhash Kumar Amarnath, Sugumaran Clin Med Insights Endocrinol Diabetes Review Article Sulfonylureas (SUs) are one of the commonly prescribed oral anti-hyperglycemic agents (AHA) in low- and middle-income countries (LMICs), either in combination with metformin therapy or alone. However, concern about cardiovascular safety has limited the use of SUs in the management of type 2 diabetes mellitus (T2DM). Additionally, lack of uniformity in the national and international guidelines regarding the positioning of SUs in the management of diabetes has also been reported. The objective of this review was to assess the various national and international guidelines on diabetes management and understand the recommendations specific to SUs in various scenarios. A total of 33 national and international guidelines on the management of T2DM published in English were evaluated. These guidelines have considered the latest evidence and suggest the use of certain second-generation SUs as second-line therapy or in combination with other AHAs in select population and specific scenarios. Identification of the appropriate population, classification based on underlying risk, thorough assessment of the comorbid conditions, and a step-wise approach for the selection of appropriate SUs is essential for the effective management of T2DM. Additionally, cost-to–benefit ratio should be considered, particularly in LMICs, and SUs could continue to play an important role in such settings. SAGE Publications 2022-02-14 /pmc/articles/PMC8854230/ /pubmed/35185350 http://dx.doi.org/10.1177/11795514221074663 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Article Mohan, Viswanathan Saboo, Banshi Khader, Jabbar Modi, Kirtikumar D Jindal, Sushil Wangnoo, Subhash Kumar Amarnath, Sugumaran Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines |
title | Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines |
title_full | Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines |
title_fullStr | Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines |
title_full_unstemmed | Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines |
title_short | Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines |
title_sort | position of sulfonylureas in the current era: review of national and international guidelines |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854230/ https://www.ncbi.nlm.nih.gov/pubmed/35185350 http://dx.doi.org/10.1177/11795514221074663 |
work_keys_str_mv | AT mohanviswanathan positionofsulfonylureasinthecurrenterareviewofnationalandinternationalguidelines AT saboobanshi positionofsulfonylureasinthecurrenterareviewofnationalandinternationalguidelines AT khaderjabbar positionofsulfonylureasinthecurrenterareviewofnationalandinternationalguidelines AT modikirtikumard positionofsulfonylureasinthecurrenterareviewofnationalandinternationalguidelines AT jindalsushil positionofsulfonylureasinthecurrenterareviewofnationalandinternationalguidelines AT wangnoosubhashkumar positionofsulfonylureasinthecurrenterareviewofnationalandinternationalguidelines AT amarnathsugumaran positionofsulfonylureasinthecurrenterareviewofnationalandinternationalguidelines |